المؤلفون: Paul M; Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, Hyderabad 500078, Telangana, India., Das S; Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, Hyderabad 500078, Telangana, India., Ghosh B; Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, Hyderabad 500078, Telangana, India., Biswas S; Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, Hyderabad 500078, Telangana, India.

المصدر: Nanomedicine (London, England) [Nanomedicine (Lond)] 2024 Jul 02; Vol. 19 (16), pp. 1431-1448. Date of Electronic Publication: 2024 Jul 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101278111 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1748-6963 (Electronic) Linking ISSN: 17435889 NLM ISO Abbreviation: Nanomedicine (Lond) Subsets: MEDLINE

مواضيع طبية MeSH: Lapatinib*/pharmacology , Lapatinib*/chemistry , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Drug Resistance, Neoplasm*/drug effects , Doxorubicin*/pharmacology , Doxorubicin*/chemistry , Doxorubicin*/administration & dosage , Nanoparticles*/chemistry , Serum Albumin, Human*/chemistry, Humans ; Female ; Animals ; MCF-7 Cells ; Rats ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/administration & dosage ; Drug Carriers/chemistry ; Receptor, ErbB-2/metabolism ; Quinazolines/pharmacology ; Quinazolines/chemistry ; Quinazolines/administration & dosage ; alpha-Tocopherol/chemistry ; alpha-Tocopherol/pharmacology ; Particle Size

المؤلفون: Talarposhti MV; Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran., Salehzadeh A; Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran. salehzadeh@iaurasht.ac.ir., Jalali A; Department of Biology, Faculty of Science, Arak University, Arak, 384817758, Iran.

المصدر: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2024 Sep; Vol. 397 (9), pp. 6855-6866. Date of Electronic Publication: 2024 Apr 02.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Lapatinib*/pharmacology , Copper*/toxicity , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/toxicity , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/metabolism , Apoptosis*/drug effects , Reactive Oxygen Species*/metabolism, Humans ; Cell Line, Tumor ; Female ; A549 Cells ; Metal Nanoparticles/toxicity ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Cell Cycle/drug effects

المؤلفون: Zhang H; Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China; Medical School, Kunming University of Science and Technology, Kunming, 650500, China., Zhang L; Academy of Biomedical Engineering, Kunming Medical University, Kunming, 650500, China., He Y; State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China., Jiang D; Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China., Sun J; The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China., Luo Q; Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China., Liang H; Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China., Wang T; Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China; School of Life Science, University of Science & Technology of China, Hefei, 230027, Anhui, China., Li F; Academy of Biomedical Engineering, Kunming Medical University, Kunming, 650500, China., Tang Y; The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China., Yang Z; State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China., Liu W; The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China. Electronic address: lwj9149@163.com., Rao Y; State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, China. Electronic address: yrao@tsinghua.edu.cn., Chen C; Academy of Biomedical Engineering, Kunming Medical University, Kunming, 650500, China; The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China. Electronic address: chenc@kmmu.edu.cn.

المصدر: Cancer letters [Cancer Lett] 2024 Aug 28; Vol. 598, pp. 217112. Date of Electronic Publication: 2024 Jul 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE

مواضيع طبية MeSH: Lapatinib*/pharmacology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Drug Resistance, Neoplasm*/drug effects , Class I Phosphatidylinositol 3-Kinases*/genetics , Class I Phosphatidylinositol 3-Kinases*/metabolism , Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/metabolism , Cell Proliferation*/drug effects , Xenograft Model Antitumor Assays* , Proteolysis*/drug effects, Humans ; Female ; Animals ; Cell Line, Tumor ; Mice ; Mutation ; Antineoplastic Agents/pharmacology ; Protein Kinase Inhibitors/pharmacology ; Mice, Nude ; Thiazoles

المؤلفون: Andriani L; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China., Ling YX; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China., Yang SY; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, 200032, China., Zhao Q; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China., Ma XY; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China., Huang MY; Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China., Zhang YL; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, 200032, China., Zhang FL; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, 200032, China. Electronic address: zhangfanglin555@sina.com., Li DQ; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, 200032, China. Electronic address: daqiangli1974@fudan.edu.cn., Shao ZM; Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China. Electronic address: zhimingshao@fudan.edu.cn.

المصدر: Cancer letters [Cancer Lett] 2024 Aug 10; Vol. 597, pp. 217008. Date of Electronic Publication: 2024 Jun 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE

مواضيع طبية MeSH: Autoantigens*/metabolism , Autoantigens*/genetics , Autophagy*/drug effects , Lapatinib*/pharmacology , Membrane Proteins*/metabolism , Membrane Proteins*/genetics , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/metabolism , Triple Negative Breast Neoplasms*/genetics , Cation Transport Proteins*/genetics , Cation Transport Proteins*/metabolism, Animals ; Female ; Humans ; Mice ; Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Disease Progression ; Gene Expression Regulation, Neoplastic/drug effects ; Intracellular Signaling Peptides and Proteins/metabolism ; Intracellular Signaling Peptides and Proteins/genetics ; Proteolysis/drug effects ; Signal Transduction/drug effects ; Xenograft Model Antitumor Assays

المؤلفون: Gurung SK; Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL, 35487, USA., Shevde LA; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35233, USA., Rao SS; Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL, 35487, USA. Electronic address: srao3@eng.ua.edu.

المصدر: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Aug 06; Vol. 720, pp. 150142. Date of Electronic Publication: 2024 May 18.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE

مواضيع طبية MeSH: Lapatinib*/pharmacology , Lapatinib*/therapeutic use , Laminin*/metabolism , Drug Resistance, Neoplasm*/drug effects , Brain Neoplasms*/metabolism , Brain Neoplasms*/secondary , Brain Neoplasms*/drug therapy , Brain Neoplasms*/pathology , Receptor, ErbB-2*/metabolism , Antineoplastic Agents*/pharmacology , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Breast Neoplasms*/drug therapy, Humans ; Cell Line, Tumor ; Female ; Triple Negative Breast Neoplasms/pathology ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/drug therapy ; Tumor Microenvironment/drug effects ; Cell Survival/drug effects ; Extracellular Matrix/metabolism ; Extracellular Matrix/drug effects

المؤلفون: Singh N; Polymer-based Medical Devices and Complex Drug Delivery Systems Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research Kolkata, Jadavpur 700032, India., Chakravarti R; Department of Natural Products, National Institute of Pharmaceutical Education and Research Kolkata, Jadavpur 700032, India., Das A; Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Kolkata, Kolkata 700054, India., Gupta S; Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Kolkata, Kolkata 700054, India., Ghosh D; Department of Natural Products, National Institute of Pharmaceutical Education and Research Kolkata, Jadavpur 700032, India., Datta P; Polymer-based Medical Devices and Complex Drug Delivery Systems Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research Kolkata, Jadavpur 700032, India.

المصدر: Molecular pharmaceutics [Mol Pharm] 2024 Aug 05; Vol. 21 (8), pp. 3921-3935. Date of Electronic Publication: 2024 Jun 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Solubility* , Lapatinib*/chemistry , Excipients*/chemistry, Humans ; Lipids/chemistry ; Salts/chemistry ; Biological Availability ; Hydrogen-Ion Concentration ; Chemistry, Pharmaceutical/methods ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/administration & dosage ; Drug Liberation

المؤلفون: Qu N; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Wang G; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Su Y; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Chen B; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Zhou D; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Wu Y; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Yuan L; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Yin M; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Liu M; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China., Peng Y; Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electronic address: pengyangpoop6@qq.com., Zhou W; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing 400016, China; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing 400016, China. Electronic address: wyzhou0118@cqmu.edu.cn.

المصدر: Biochemical pharmacology [Biochem Pharmacol] 2024 Aug; Vol. 226, pp. 116347. Date of Electronic Publication: 2024 Jun 07.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Breast Neoplasms*/drug therapy , Epithelial-Mesenchymal Transition*/drug effects , Epithelial-Mesenchymal Transition*/physiology , Lapatinib*/pharmacology , Phosphoric Monoester Hydrolases*/metabolism , Phosphoric Monoester Hydrolases*/genetics , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/genetics, Animals ; Female ; Humans ; Mice ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Mice, Inbred BALB C ; Mice, Nude ; Xenograft Model Antitumor Assays/methods

المؤلفون: Yakati V; Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL 35487, USA. srao3@eng.ua.edu., Shevde LA; Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA., Rao SS; Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL 35487, USA. srao3@eng.ua.edu.

المصدر: Biomaterials science [Biomater Sci] 2024 Jul 23; Vol. 12 (15), pp. 3882-3895. Date of Electronic Publication: 2024 Jul 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101593571 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-4849 (Electronic) Linking ISSN: 20474830 NLM ISO Abbreviation: Biomater Sci Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology , Breast Neoplasms*/drug therapy , Hydrogels*/chemistry , Hydrogels*/pharmacology , Hyaluronic Acid*/chemistry , Hyaluronic Acid*/pharmacology , Brain Neoplasms*/drug therapy , Brain Neoplasms*/secondary , Brain Neoplasms*/pathology , Lapatinib*/pharmacology , Lapatinib*/administration & dosage , Paclitaxel*/pharmacology , Paclitaxel*/chemistry , Paclitaxel*/administration & dosage , Cell Proliferation*/drug effects, Humans ; Female ; Cell Line, Tumor ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; Immediate-Early Proteins/metabolism ; Immediate-Early Proteins/antagonists & inhibitors ; Drug Resistance, Neoplasm/drug effects ; Protein Serine-Threonine Kinases/metabolism ; Protein Serine-Threonine Kinases/antagonists & inhibitors

المؤلفون: Mansour HM; Central Administration of Biologicals, Innovative Products, and Clinical Studies, Egyptian Drug Authority, EDA, Giza, Egypt., Mohamed AF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt; Faculty of Pharmacy, King Salman International University (KSIU), South Sinai 46612, Egypt. Electronic address: Ahmed.fathi@pharma.cu.edu.eg., Khattab MM; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt., El-Khatib AS; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

المصدر: Brain research [Brain Res] 2024 Jul 01; Vol. 1834, pp. 148893. Date of Electronic Publication: 2024 Mar 28.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 0045503 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-6240 (Electronic) Linking ISSN: 00068993 NLM ISO Abbreviation: Brain Res Subsets: MEDLINE

مواضيع طبية MeSH: Dopaminergic Neurons*/drug effects , Dopaminergic Neurons*/metabolism , ErbB Receptors*/metabolism , ErbB Receptors*/antagonists & inhibitors , Lapatinib*/pharmacology , Parkinsonian Disorders*/drug therapy , Parkinsonian Disorders*/metabolism , Parkinsonian Disorders*/chemically induced , Receptors, Dopamine D3*/metabolism , Receptors, Dopamine D3*/antagonists & inhibitors , Rotenone*, Animals ; Male ; Rats ; Dopamine/metabolism ; Oxidative Stress/drug effects ; Signal Transduction/drug effects ; Substantia Nigra/drug effects ; Substantia Nigra/metabolism ; Tyrosine 3-Monooxygenase/metabolism

المؤلفون: Gunasekara ADM; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.; Department of Paraclinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Ratmalana, Sri Lanka., Youngkong S; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. sitaporn.you@mahidol.edu.; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudhaya Rd., Phayathai, Ratchathevi, Bangkok, Thailand. sitaporn.you@mahidol.edu., Anothaisintawee T; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.; Department of Family Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Dejthevaporn T; Division of Medical Oncology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Fernandopulle R; Department of Paraclinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Ratmalana, Sri Lanka., Chaikledkaew U; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudhaya Rd., Phayathai, Ratchathevi, Bangkok, Thailand.

المصدر: Scientific reports [Sci Rep] 2024 Jul 20; Vol. 14 (1), pp. 16736. Date of Electronic Publication: 2024 Jul 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/economics , Breast Neoplasms*/metabolism , Receptor, ErbB-2*/metabolism , Neoadjuvant Therapy*/economics , Cost-Benefit Analysis* , Trastuzumab*/therapeutic use , Trastuzumab*/economics , Lapatinib*/therapeutic use, Humans ; Female ; Sri Lanka ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/economics ; Markov Chains ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/economics ; Quality-Adjusted Life Years ; Budgets ; Middle Aged